Recent decades have seen dramatic changes in the management of prostate cancer based on novel research findings.
Prostate-specific antigen (PSA) screening has been introduced, and then recently modified to include new strategies and biomarkers. Management of advanced disease has been transformed by the rapid introduction of new agents. We have moved from a "one-size-fits-all" approach in prostate cancer management to multidisciplinary strategies tailored to the individual patient and his specific cancer. This editorial marks the launch of the article collection Spotlight on prostate cancer (http://www.biomedcentral.com/bmcmed/series/SPR), and here, guest editors Sigrid Carlsson and Andrew Vickers give an overview of the past, present, and future of prostate cancer research and management.
Written by:
Carlsson S, Vickers A. Are you the author?
Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Reference: BMC Med. 2015 Mar 24;13:60.
doi: 10.1186/s12916-015-0311-x
PubMed Abstract
PMID: 25857774